(Q38032320)

27 August 2017

title

Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens (English)

1 reference

lymphoproliferative disorders

27 August 2017

1 reference

1 reference

Vidhya Murukesan

1

1 reference

27 August 2017

Sandeep Mukherjee

series ordinal

2

1 reference

27 August 2017

publication date

1 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1631-1643

1 reference

https://scigraph.springernature.com/pub.10.2165/11635690-000000000-00000

27 August 2017

exact match

0 references

cites work

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment advances in posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Laboratory assays for Epstein-Barr virus-related disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Utility of mTOR inhibition in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Epstein-Barr virus, rapamycin, and host immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Monoclonal antibody therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Rituximab: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

EBV-associated lymphoproliferative disorders: classification and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of PTLD with rituximab or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Lymphoproliferative disorders in Oxford renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Posttransplant lymphoproliferative disorder: significance of central nervous system involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Natural killer-cell malignancies: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Low-dose radiation for posttransplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Immunization and transplantation--what is new and what is coming?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Lymphomas occurring late after solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

Conversion to Rapamycin Immunosuppression for Malignancy After Kidney Transplantation: Case Reports

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635690-000000000-00000

BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.

21 January 2018

1 reference

12 December 2020

Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients

1 reference

12 December 2020

Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

1 reference

12 December 2020

Lymphomas after solid organ transplantation: a collaborative transplant study report

1 reference

12 December 2020

Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients

1 reference

12 December 2020

Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center

1 reference

12 December 2020

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 reference

12 December 2020

Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop

1 reference

12 December 2020

The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients

1 reference

12 December 2020

Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?

1 reference

12 December 2020

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

1 reference

12 December 2020

Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation

1 reference

12 December 2020

Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome

1 reference

12 December 2020

First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen

1 reference

12 December 2020

Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation

1 reference

12 December 2020

Incidence and consequences of post-transplantation lymphoproliferative disorders

1 reference

12 December 2020

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

1 reference

12 December 2020

Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.

1 reference

12 December 2020

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

12 December 2020

The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders

1 reference

12 December 2020

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

1 reference

12 December 2020

10.2165/11635690-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1035153275

0 references

1 reference